* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download document
Survey
Document related concepts
Transcript
Applications of Photosensitisers to Cancer, Viral, Bacterial Disease and Immunology Terry Wright http://www.cytoluminator.com Non-toxic Sensitizer Photosensitising agent •Dye molecule •Not cytotoxic •Taken up by cell (i.e. staining) Cell Survives Cell Tuned Laser Light Light exposure Light (Red) •Red or near IR •Cell is transparent •Not cytotoxic •No heating Cell Survives Cell ROS Flood = Death PS + Light Light (Red) •Cell not transparent •Energy is absorbed •Reactive oxygen species •Oxidative stress Cell Dies!! Cell Chemical Targeting Nanomolecular Delivery • • • • Proprietary sensitiser formulation 20 nm nanoparticles containing sensitiser Cationic surface charge targets cancer Reduced sensitisation of healthy tissue – Eyes – Skin • Rapid clearance – 1wk vs 6 Nanomolecular Delivery Accumulation of sensitizer in skin of Bufo Marinus with nanomolecule Same sensitizer and same dose without nanomolecule formula Gentle Death • High dose: necrosis • Minimum dose: apoptosis – – – – Sensitiser bound to mitochondrial membrane Cleave Bcl-2 / Bcl-XL Loss of mitochondrial membrane potential Programmed cell death follows PDT of Cancer • Barret’s Oesophagus • Adjunct therapy for solid tumours – Systemic administration – Non-surgical debulking – Killing microscopic remnants • Topical application for non-melanoma SC • Glioblastoma Multiforme at RMH – 50% survival at 10 yr, vs ~5% at 2 yr chemo S. S. Stylli and A. H. Kaye, J. Clin. Neurosci. 13, 709-717 (2006) PDT Causes in-situ Vaccination • Adaptive immunity frequently observed • Remote metastases controlled / eliminated – Tc / NK cells, macrophages • Animal models resistant to rechallenge • Adoptively transferable • Inflammation due to necrosis, immune response due to apoptosis? F.H. van Duijnhoven et al., Immunobiol. 207, 105-113 (2003). Activating the Immune System • Because PDT creates a perfect vaccination against the cancer in the patients body, the immune system immediately begins to attack the cancer. • With antibody therapy the suppressor t-cells are activated. • When killing a large tumor up to 95% of the bodies white cells rush to attack the cancer Disabling the Defense • Cancer mounts a defense against the immune system. • T-cells are converted to suppressor cells which suppress new TIL. • Immature myeloid cells are converted to suppressors via ROS. • Antibodies disable the defense systems mounted by cancer to enable immune attack Risk Factors with PDT • High level necrotic kills can cause swelling and inflammation- severe risk for brain tumors. • Even with apoptotic kills the amount of cancer killed can be huge. • Toxin load can be challenging for hepatic and renal elimination, so maintainance of organ health is vital. Absorption/Fluorescence Spectra λ = 685 nm (excitation) Fluorescence detection Absorption Emission Detection of Fluorescence • Laser excitation • Near-IR fluorescence • Camera with IR filter Laser: 685nm IR: 695-780nm Image on PC Screen Lymphatic Involvement When cancer is not present in lymph nodes, no fluorescence is seen, as in the left picture above. When cancer is present, photodynamic fluorescence is very obvious. A few minutes of laser will resolve this condition. Metastatic Bone Cancer • Patient 2: metastasis in the manubrium Before Treatment After Treatment Metastatic Bone Cancer • Skull mets • Ankle mets Post-Salvage Breast Cancer Following surgery, chemotherapy and radiotherapy Post-Salvage Breast Cancer Following Photodynamic Therapy Post-Salvage Breast Cancer Psoriasis • Active leukocytes accumulate sensitiser • Topical PDT of skin autoimmune disorders Psoriasis treated with our sensitiser Two weeks later Scleroderma • Scleroderma Treated over two years ago • No indication of return to date Scleroderma treated with our sensitiser Multiple Sclerosis Before treatment After treatment Multiple Sclerosis treatment is remarkably easy. A one hour infusion with laser illumination at the same time resets the immune system resulting in long lasting remission of symptoms Diabetes Diabetes Mellitus type I has been treated in animal models. Mice genetically programmed to develop DM I treated with PDT have a 60% lower chance of developing DM I. Both types of Diabetes are now being considered as autoimmune diseases. In one diabetic patient treated for cancer, blood sugar levels dropped from 10+ to six range within days after treatment. Diabetic Wound Healing Wounds which normally don’t heal for days or weeks can be treated with a topical application of sensitizer and a few minutes of laser. Wound healing proceeds normally after treatment Bacteria Golden Staph has been tested to 20 generations of LD 50 kills It has never shown indication of developing resistance to PDT. PDT for golden staph can be delivered fast and cost effectively. In Staph from recent injuries or surgeries, the sensitizer can be administered topically and will absorb through the wound. Bloodborne golden staph can be treated with IV infusions. Conclusion • • • • PDT: a clinical reality in most developed countries But Australia is trailing ~15 years behind No sensitiser approved for systemic use Locally developed and manufactured: – Portable laser, >5W at present and >10W planned – Photosensitisers: systemic, intratumoural, topical – IR camera and uniform illumination Questions? http://www.cytoluminator.com